ONO-7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study.

Dominic BealeJeremy DennisonMalcolm BoyceFrancesca MazzoNaoki HondaPaul SmithMark Bruce

Published in: British journal of clinical pharmacology (2021)

The data generated in this FIH study demonstrate the promising potential of oral FXIa inhibition and ONO-7684 for indications requiring anticoagulation.

Keyphrases

atrial fibrillation
clinical trial
venous thromboembolism

randomized controlled trial
machine learning

electronic health record
induced pluripotent stem cells

artificial intelligence
data analysis